TC 220 - TAE Life Sciences
Alternative Names: TC-220 - TAE Life SciencesLatest Information Update: 17 Aug 2023
Price :
$50 *
At a glance
- Originator TAE Life Sciences
- Class Antineoplastics; Drug conjugates; Monoclonal antibodies; Radioisotopes; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 15 Aug 2023 TAE Life Sciences plans to file an IND application with the US FDA in USA for Cancer before 2024
- 15 Aug 2023 TAE Life Sciences plans clinical trial for Cancer in the US and EU in 2024
- 17 Jul 2023 Preclinical trials in Solid tumours in USA (IV) (TAE Life Sciences pipeline, July 2023)